A securities class action pending against APYX has survived a motion to dismiss. That case alleges that Apyx misled investors about its 2018 J-Plasma FDA application, causing Apyx's stock to trade at artificially inflated prices. 

Grabar Law Office is investigating potential derivative claims based on harm the company has suffered as a result of potential breaches of fiduciary duty by the company's officers and directors.  To learn more, message me here or email jgrabar@grabarlaw.com